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As the UK exits the European Union, there is a press-
ing need for the UK to invest in regulatory science
and innovation if it is to be globally competitive and
internationally collaborative. Innovation in life
sciences, including digital tools, robotics, artificial
intelligence and new therapeutic approaches, such
as cell and gene therapy, will play a crucial role in
continued improvement in health outcomes and life
expectancy. The UK is powerfully positioned to lead
in the discovery, development and evaluation of these
new approaches, enabling accelerated routes to
market, increasing benefits to public and individual
health, improving patient safety, influencing interna-
tional practice and promoting investment in the
UK.1,2
Advances in regulatory science, or ‘the application
of the biological, medical and sociological sciences to
enhance the development and regulation of medicines
and devices in order to meet the appropriate stan-
dards of quality, safety and efficacy’,3 matter more
than ever to inform and evaluate new approaches to
regulating these innovative technologies. In this com-
mentary piece, we argue that the UK has a unique
opportunity to advance regulatory science and inno-
vation and drive global advances in this area and
make a series of recommendations to this end based
on key findings from Birmingham Health Partners
Advancing Regulatory Science and Innovation in
Healthcare Report (Box 1).4,5 The UK should take
a coordinated approach to foster and prioritise
advances in regulatory science and innovation and
build a workforce to ensure its sustainability and con-
tinuing evolution. We should actively support the
emergence of both existing and new clusters in regu-
latory science. Support for these clusters should draw
on world-leading academic expertise, leverage
increasingly integrated regional ecosystems, connect-
ing industry, policy and the NHS and – crucially – the
voices of our patients and citizens (Box 2).
Current context for regulatory science
Life sciences are vital to the UK’s health but also its
economic wealth. The industry supports around
482,000 jobs in the country and the activities of life
sciences companies directly contributed £14.5bn to
the national economy in 2015, with an additional
£15.9bn provided through the life sciences supply
chain and employee spending.6 UK life sciences busi-
nesses face unprecedented challenges in both near-
term viability and long-term sector sustainability
due to regulatory uncertainty following Brexit and
the global COVID-19 pandemic.
As a European Union member, the UK Medicines
and Healthcare Products Regulatory Agency was
integrated in the European Union Medicines
Regulatory Network, including the European
Medicines Agency. Now that the UK has left the
European Union, the Medicines and Healthcare
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Products Regulatory Agency will ‘continue to sup-
port the UK Government to deliver its legal obliga-
tions under the Withdrawal Agreement and prepare
for its new relationships with the European Union
and the rest of the world’. To do this, they continue
to work closely with the Department of Health and
Social Care to ensure the UK regulatory environment
works in the best interests of patients, industry and
Box 1. Recommendations.a
Strategic leadership and coordinated support
 A specific national healthcare/life sciences strategic advisory committee should be established to provide dynamic oversight to
complement the UK’s new Regulatory Horizon Council, enabling multidisciplinary and cross-sector input to advance UK
healthcare regulation and promote innovation informed by regulatory science. Dynamic oversight should be provided in
accordance with principles specified by the Wellcome Trust blueprint (inclusive, anticipatory, innovative and proportionate).
 The Medicines and Healthcare Products Regulatory Agency should work with stakeholders – including the devolved admin-
istrations in Scotland, Wales and Northern Ireland – to develop a UK strategy for regulatory science to create a roadmap for
national efforts, to maximise the speed of UK medicines regulation and health technology evaluation.
 Major UK funding bodies – including UK Research and Innovation, the National Institute for Health Research and members of
the Association of Medical Research Charities – should identify potential funding mechanisms for regulatory science which
could deliver major benefits aligned to their respective remits and communities.
Enabling innovation
 Given challenging timelines around the Brexit transition period, multi-stakeholder work is needed to understand and prioritise
specific technological or methodological areas in which the UK’s capability for regulatory innovation could enable a global
leadership position, delivering major economic and healthcare benefits. The UK should maintain high levels of regulatory
compatibility and fully understand the threats and opportunities posed by any divergence.
 Emerging technologies should be identified through horizon scanning and where uncertainties arise about how to regulate
certain emerging technologies; we need joint working processes enabling regulatory bodies and industry to flag where
evidence and innovation are required in regulatory science to justify research and development investments.
 Innovation in regulatory science is needed to underpin an R&D environment that mitigates ‘high-risk’ areas of investment with
significant promise – for example, antimicrobial resistance or new medications for pregnancy-related conditions.
 Specific consideration should be given to supporting regulatory science aligned to the Accelerated Access Collaborative,
establishing how the uptake of innovation within the National Health Service can be better enabled, and how local good
practice can help drive wider national behaviours.
Implementation and evaluation
 We need to establish coordinated national and international approaches for promotion of new guidance, including develop-
ment of implementation tools and resources and training and establishing how regulators, industry bodies, funders, healthcare
providers and other agencies can act in concert to accelerate implementation.
 An evaluation framework with agreed metrics should be developed to assess the impact of regulatory innovation and
implementation.
 International stakeholders must work collaboratively to understand the benefits and challenges of changes in regulation, such
as those arising from COVID-19, and how this could be applied to other settings.
Workforce development
 A scoping exercise should be undertaken to more fully understand specific training needs across various stakeholder groups to
support regulatory science innovation and improve uptake/use of innovative technologies and medicines.
 The UK should seek to establish clear career pathways in regulatory science, via internships, fellowships or PhDs involving
academia, industry, National Health Service, patient partners and regulatory bodies as key collaborators, mentors and
beneficiaries.
aRecommendations taken from Birmingham Health Partners Advancing Regulatory Science and Innovation in Healthcare Report, 2020, based on a
scoping review and stakeholder input.4
MHRA: Medicines and Healthcare Products Regulatory Agency; R&D, research and development.
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our partners across the health and care system.’4,7
The Medicines and Healthcare Products Regulatory
Agency Business Plan 2020–2021 highlights key stra-
tegic areas for change ‘in response to the need to
develop a new and effective regulatory model, but
this also reflects a new focus on involving and enga-
ging with patients, enabling patient access to new
innovative medicines and devices, and speedier
response to risks to patient safety and public
health.’7 A key strategic objective is to improve reg-
ulatory science. Post-transition, we should use the
European Union–UK negotiations to maintain their
current high level of regulatory compatibility, while
contributing to advancing global regulations. How
should the UK do this? First, it must take account
of clear clinical and academic strengths to inform
regulatory innovation. Second, it must factor in the
opportunity for UK industry to invest in innovation
and create a national testbed to drive global progress.
The life sciences industry has already invested sig-
nificant effort and funds to prepare for new European
Union frameworks, and incompatibility from the UK
brings risks around complexity, competence and
capacity. Our UK trade associations – providing
insight and ongoing engagement – have given us a
robust framework that we should harness to mitigate
these risks. The Government’s White Paper on
‘Regulation for the Fourth Industrial Revolution’
noted that:
We need to reshape our regulatory approach so that
it supports and stimulates innovation that benefits
citizens and the economy. At present, only 29% of
businesses believe that the government’s approach to
regulation facilitates innovative products and ser-
vices being efficiently brought to market. The need
for reform is urgent: 92% of businesses from a range
of sectors think they will feel a negative impact if
regulators don’t evolve to keep pace with disruptive
change in the next two to three years.1
COVID-19 has severely impacted life sciences
research and development, while also demonstrating
the impact of a more collaborative effort and regula-
tory flexibility. The sector is looking at resilient
recovery while recognising the continued risk of dis-
ruption. During this recovery phase, pharmaceutical
and medical technology companies have asked for
continued, (national and international) regulatory
flexibility. They have used flexibility as they acceler-
ate product development in medicines, devices and
vaccines, and move to re-initiate trials, mitigate miss-
ing data and implement new models of working
(including telehealth and remote monitoring). The
unprecedented events of the pandemic have offered
a paradigm shift in healthcare regulation.8,9
Strategic leadership and coordinated
support
The UK Government’s White Paper, Regulation for
the Fourth Industrial Revolution, notes:
As we leave the European Union and forge a new
path for ourselves, we will continue to play an impor-
tant role in shaping how regulation is developed
internationally. We will collaborate with like-
minded international partners to reduce regulatory
barriers to trade, through mechanisms such as the
adoption of international standards, mutual recogni-
tion agreements and free trade agreements. We will
encourage our regulators to play an active role in
shaping international thinking on how innovation
should be regulated.1
Box 2. The need for meaningful and sustained patient and citizen involvement.
Patients and society are beneficiaries of scientific discoveries, new technologies and improved medications; but they also can and
should be able to contribute to these discoveries through participation in clinical studies and in the co-design of research.
Patients, as well as our wider, diverse communities, can provide unique insights into which specific healthcare problems and
priorities these discoveries, technologies and medications should be targeted; what kind of evidence validates their effective-
ness; and what ‘value’ truly means in terms of our health and treatment outcomes. Trust and transparency are more critical than
ever. Patients want better treatments as quickly as possible, but not at the cost of safety, privacy or awareness of risk. Laws,
regulations and standards play a vital role in enshrining patients’ and citizens’ requirements and innovators’ responsibilities.
Where these are adapting – which we recognise they must, to respond to the scale and pace of opportunity in healthcare – it is
essential that patients and citizens have a voice and are accepted as true partners in these endeavours. Patients and citizens can
provide the lived experience and deeply meaningful insights into all aspects of healthcare and in regulatory science initiatives.
‘We need to develop a more sophisticated model of engagement where ethical and moral issues arise and ensure that issues
such as risk and uncertainty are discussed appropriately. We need to build trust and enable consumers to have confidence in
innovations and businesses to have confidence in our stable and proportionate regulatory system.’1
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For the UK to maximise opportunities in the
future regulation of healthcare innovation, it must
work cohesively and collaboratively while creating
an environment that gives innovators faster ways to
demonstrate benefit. The UK must leverage the high
profile and excellent stakeholder engagement pro-
cesses of the leading players. These organisations
include: the NHS, patient organisations, National
Voices, academia, the Medicines and Healthcare pro-
ducts Regulatory Agency, the NICE and Health
Research Authority, as well as the Association of
the British Pharmaceutical Industry, Association of
British HealthTech Industries, Accelerated Access
Collaborative, the British In Vitro Diagnostic
Association and Health Data Research Alliance,
coordinated by Health Data Research UK, which
aims to establish best practice around the ethical
use of UK health data for research and innovation
at scale.10 Expert regulatory science should support
them.
To gain these crucial inputs, we will need colla-
boration across multiple stakeholders and strategic
leadership. Meaningful patient and citizen involve-
ment should be central to all activities (Box 2).
Additionally, we require alignment with the new
Regulatory Horizons Council.11 This independent
expert committee identifies the implications of tech-
nological innovation; it provides the government with
impartial, expert advice on the regulatory reform
required to support the rapid and safe introduction
of new technologies.
The growth of the Academic Health Science
Networks has complemented the emergence of signif-
icant academic–NHS partnerships.12 Additionally,
Life Science Opportunity Zones support major indus-
try-facing centres of gravity. Together, these areas
have become ready-made research ‘clusters’ for inno-
vation – and an ideal springboard for regulatory
science to flourish in the UK.13 Through increased
ease of collaboration, clusters foster shared knowl-
edge and talent pools, support collaborative cross-
sector innovation and generate synergistic value.
They provide essential accelerators and testbeds to
inform broader systems thinking.
An ongoing commitment to international colla-
boration will also be key. It would be highly dama-
ging for the UK to attempt to operate fully in
isolation of other regulatory systems and interna-
tional excellence in approaches to supporting emer-
ging technologies and regulatory science.2 Indeed, we
can and should learn from global regulatory science
initiatives such as the research programmes and cen-
tres of excellence supported by the Food and Drug
Administration (FDA) in the US and the Clinical
Trials Transformation Initiative.5,14
Prioritisation and shared risk
Regulatory science – where appropriately targeted –
offers a way to provide clarity and collaboration
between stakeholders. There are several emerging
technologies and trends in regulation which need col-
lective visions on how best to move forward, as high-
lighted by recent Regulatory Science Summits
organised by the Innovative Medicines Initiative in
collaboration with the European Medicines Agency
and FDA and the European Medicines Agency’s
Regulatory Science to 2025 strategy.15,16 These tech-
nologies include: advanced therapy medicinal pro-
ducts, artificial intelligence, digital tools for data
collection and analysis, digital therapeutics, immu-
nology and the microbiome, big data and digital
health, as well as real-world evidence and clinical
trials.
International horizon scanning should proactively
identify emerging healthcare technologies. Where
uncertainties arise about appropriate regulation, we
need joint working processes that enable regulatory
bodies and industry to flag where evidence and inno-
vation are required in regulatory science to justify
research and development investments. Interaction
with patient organisations and enhancing methods
to incorporate patient-relevant evidence in benefit-
risk evaluation and regulatory decision making is
key. Tools include patient-reported outcomes and
patient preference data.15 Products, services and busi-
ness models with high potential benefit for UK
society and the economy should be prioritised.
Innovation in regulatory science is vital to underpin
a research and development environment that miti-
gates ‘high-risk’ areas of investment with significant
promise, such as antimicrobial resistance or new med-
ications for pregnancy-related conditions, to facilitate
the rapid and safe introduction of these products and
services.17 Early engagement of innovative developers
with multi-stakeholder scientific advice (for example,
joint meetings offered by the Medicines and
Healthcare Products Regulatory Agency Innovations
Office and NICE), offers benefits to all; facilitating
navigation of the regulatory landscape and identifying
challenging areas for regulators to address.18
Implementation and evaluation of
regulatory innovation
New tools and methodologies will be needed to prop-
erly evaluate the impacts of regulatory change and
support continuous iteration – the building blocks
for these have already been established nationally
and internationally. In 2012, the Organisation for
Economic Co-operation and Development (OECD)
published a framework for systematically
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evaluating the performance of regulations and regu-
latory policies.19 Measuring regulatory progress in a
meaningful and credible way requires indicators to
measure relevant outcomes and appropriate research
designs. Both are needed to support inferences
about the extent to which a regulation or regulatory
policy under evaluation has actually caused a
change in the measured outcomes. Indicators may
include: (1) impact/effectiveness (changes in the pro-
blem or other outcomes of concern such as patient
safety, mortality); (2) cost-effectiveness (costs for a
given level of impact); (3) net benefits (all beneficial
impacts minus all cost impacts); and (4) equity/
distributional fairness of impacts. In addition to
equity or distributional concerns, sometimes other
outcomes of interest are used as criteria, such as
impacts on technological innovation, macroeconomic
growth, and employment. Building on the
Organisation for Economic Co-operation and
Development framework, the European Medicines
Agency has developed a conceptual framework for
the review of the impact of regulatory science projects
on its regulatory processes and activities – with impli-
cations for resources and further iterative improve-
ments (Box 3).19
We believe that we need ‘parallel not series’ eva-
luation, regulation and implementation processes,
underpinned by training. Additionally, we require
development platforms that: bring together innova-
tors, regulators and end-users to map out innovation
journeys; create consensus for the use of novel tech-
nologies; devolved flexibility to enable real-world
testing of regulatory adaptation before scaling
nationally.
Workforce development
Developing a coherent UK programme of training in
regulatory science will be crucial to delivering
workforces for industry, the NHS, policy and acade-
mia and to support patients and the public involved
in regulatory science initiatives. This is an urgent
priority to bridge the potential expertise gap resulting
from leaving the European Medicines Regulatory
Network and to advance regulatory science in the
UK. It will provide a sustainable skills pool to
ensure that technological innovation in healthcare
can be supported successfully – and the correspond-
ing health and economic benefits are realised – while
robustly protecting patients. However, we also need
to understand what each of these diverse stakeholders
in regulatory science need – and what they can offer –
so that we can assemble a clear national framework
and strategy. Current UK-based training is somewhat
limited, comprising master’s level training/appren-
ticeships and continuing professional development,
emerging technologies will require a higher level of
capability.20 To keep pace with innovation and inter-
national counterparts, the programme needs to be
expanded via internships, fellowships and PhDs
involving academia, industry, professional bodies,
National Health Service and regulatory bodies as
key collaborators, mentors and beneficiaries. The
UK should seek to establish clear career pathways
in regulatory science.
The UK can learn from, and engage with, interna-
tional initiatives. In the US, the FDA offers a pro-
gramme of internships and fellowships via its Oak
Ridge Institute for Science and Education partner-
ship.21 The programme allows the FDA to target
and accelerate key areas of regulatory science which
will support its future activities with successful
Fellows often going to work for the regulator and
in turn mentoring future Fellows. In the European
Union, the European Medicines Agency is currently
designing two curricula through the Strengthening
Training of Academia in Regulatory Science
‘STARS’ initiative to support both the professional
Box 3. European Medicines Agency conceptual framework for the review of the impact of regulatory science projects on regulatory
processes and activities.
Key considerations include:
(i) When are results of regulatory science projects matured enough to form a basis to implement changes in regulatory or
clinical practice?
(ii) Depending on the types of outcomes, to what extent should results/recommendations from regulatory science projects be
validated, scrutinised and peer reviewed in the scientific community before their implementation?
(iii) Should there be a trade-off between timing of implementation and scientific replication/validation?
(iv) Which outcomes should be prioritised for implementation? Regulatory science projects delivering both the highest impact
and efficient use of resources should be prioritised.
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training of clinical scientists and a broader pro-
gramme to support a shared post graduate educa-
tional agenda,22 while the global association for
people working in Regulatory Affairs (TOPRA)
offer significant training opportunities for profes-
sionals.23 It will be crucial to leverage their expertise,
insights and professional standing to create an appro-
priately competitive and ambitious, forward-looking
training programme for the UK.
Underpinning the advancement of the sector is also a
need for people with regulatory skills, across indus-
try, the health service and academia as well as regu-
lators, not only to do the core work of medicines
development, regulation and delivery to patients
but to be resourced to develop standards for emer-
ging technologies and methodologies.2
Conclusion
The UK’s current situation brings significant com-
plexities, challenges and risks. However, our uniquely
collaborative and dynamic national ecosystem for
regulatory science is more than capable of rising to
tackle them and ensuring this is the time of unique
opportunity and benefit.
Why do these proposals matter? We have recom-
mended actions that – crucially – can put the UK in a
leadership position for regulation. This position will
attract the most exciting ideas and strategic resources
from the global industry. It will further accelerate the
co-creation and adoption of innovation by the NHS.
Critically for regulators, it will create all-important
academic insights into the tools, technologies and
methodologies they need. And most importantly, it
will give our patients and the public an integral voice
in the design, development and delivery of innovative
new treatments, diagnostics and medical devices. This
is an opportunity to develop our regulatory science
strategy for the UK to benefit the world.
Declarations
Competing interests: KO states that she has no real or per-
ceived conflicts of interests with regard to her co-authorship of this
paper but for the sake of transparency she states the following:
Between 2005 and 2020, the IBTA has received unrestricted educa-
tional grants and financial support and/or support in kind either as
an individual organisation or as part of a wider grouping of patient
organisations, from the following companies and trusts: AbbVie,
Accuray, Antisense Pharma, Apogenix, Archimedes, Ark
Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Brain
Tumor Network (USA), Brain Tumor Resource and Information
Network (USA), Bristol-Myers Squibb (BMS) Celldex
Therapeutics, Celgene, Crusade, Dijon Designs (UK), Elekta, Eli
Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling
Foundation (UK), GlaxoSmithKline (GSK), GW
Pharmaceuticals, Incyte, Ivy Foundation (USA), Lilly, Link
Pharmaceuticals, MagForce, Medac, Merck Serono, Merck,
MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy
(Australia), Northwest Biotherapeutics, Novartis, Novocure,
Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic,
Roche, Schering-Plough (Global), Sontag Foundation (USA),
Spink (UK), STOPheresetumoren.nl, to-BBB, Vane Percy (UK),
VBL Therapeutics and the Wallerstein Foundation (USA). KO, on
behalf of Kathy Oliver Consulting, has also in this same period
received consultancy fees from Lilly, GSK, Bayer, SPAEN and
Novartis. For further details of the IBTA’s sponsorship policy,
please see https://theibta.org/become-a-corporate-sponsor/. MC
has received personal fees from Astellas, Takeda, Merck, Daiichi
Sankyo, Glaukos, GSK and the Patient-Centered Outcomes
Research Institute (PCORI) outside the submitted work.
SH is an employee of the Association of the British
Pharmaceutical Industry. MS, BT and SCR declare no conflict
of Interest.
Funding: The Birmingham Health Partners Advancing
Regulatory Science and Innovation in Healthcare Report and this
commentary piece were funded by a Quality-related (QR) research
grant from Research England.
MJC is a National Institute for Health Research (NIHR)
Senior Investigator and receives funding from the National
Institute for Health Research (NIHR) Birmingham Biomedical
Research Centre, the NIHR Surgical Reconstruction and
Microbiology Research Centre and NIHR ARC West Midlands
at the University of Birmingham and University Hospitals
Birmingham National Health Service Foundation Trust, Health
Data Research UK, Innovate UK (part of UK Research and
Innovation), Macmillan Cancer Support, UCB Pharma.
AKD receives funding from Health Data Research UK, an
initiative funded by UK Research and Innovation, Department
of Health and Social Care (England) and the devolved administra-
tions, and leading medical research charities. AKD also receives
funding from the Wellcome Trust, the NIHR Biomedical Resource
Centre (Moorfields Eye Hospital/UCL) and the Regulatory
Horizons Council. The views expressed in this article are those of
the author(s) and not necessarily those of the NIHR, the
Department of Health and Social Care, the Regulatory Horizons
Council or the Department for Business, Energy and Industrial
Strategy.
Ethical Approval: Not required
Guarantor: MJC.
Contributorship: This commentary piece is based on the
Birmingham Health Partners Advancing Regulatory Science and
Innovation in Healthcare Report 20204 and recommendations
therein, which was co-authored by MS, EM and MJC. MJC pre-
pared the initial draft of this commentary piece. All co-authors
critically reviewed the manuscript and approved the final version.
MJC is the Director of the Birmingham Health Partners Centre for
Regulatory Science and Innovation. KO is a patient advocate and
Chair of the International Brain Tumour Alliance (IBTA). AKD is
the Artificial Intelligence Lead for the Birmingham Heath Partners
Centre for Regulatory Science and Innovation, and Director of
INSIGHT, the HDRUK Health Data Research Hub for Eye
Health. SH is the Quality, Regulatory Science and Safety policy
director of the Association of the British Pharmaceutical Industry
and thus represents the views of the research-based pharmaceutical
industry in the UK. KO, patient advocate, contributed to writing
the article, providing the content for Box 2 and contributing cri-
tical revisions to the manuscript at all stages.
6 Journal of the Royal Society of Medicine 0(0)
Acknowledgements: We would like to thank contributors to
the Advancing Regulatory Science and Innovation in Healthcare
Report (Reference 4, page 73) from which this commentary is
derived.
Provenance: Provenance: Not commissioned; the paper was
revised following peer review comments from another journal
ORCID iD: Melanie J Calvert https://orcid.org/0000-0002-
1856-837X
References
1. Department for Business Energy and Industrial
Strategy. Regulation for the Fourth Industrial
Revolution. White Paper. p.37. https://www.gov.uk/
government/publications/regulation-for-the-fourth-
industrial-revolution (accessed 9 March 2020).
2. Bell J. Life Sciences Industrial Strategy. A report to the
Government from the life sciences sector. p.75. https://
www.gov.uk/government/publications/life-sciences-
industrial-strategy (accessed 06 May 2020).
3. Faulkner S. The development of regulatory science in the
UK: a scoping study. London, UK: CASMI, 2018, p.30.
4. Samuels M, Marston E and Calvert M. Advancing
Regulatory Science and Innovation in Healthcare,
www.birminghamhealthpartners.co.uk/regulation-mat-
ters-major-report-launched-by-birmingham-health-
partners/ (accessed 10 September 2020).
5. U.S. Food and Drug Administration. Advancing reg-
ulatory science at FDA: a strategic plan. p.37. August
2011, https://www.fda.gov/science-research/advancing-
regulatory-science/strategic-plan-regulatory-science.
(accessed 19 June 2020).
6. PwC. The economic contribution of the UK Life
Sciences industry, 2017. https://www.abpi.org.uk/
media/1371/the_economic_contribution_of_the_uk_
life_sciences_industry.pdf (accessed 4 April 2020).
7. MHRA. Medicines and Healthcare products
Regulatory Agency Business Plan 2020 to 2021. 2020,
https://www.gov.uk/government/publications/medi-
cines-and-healthcare-products-regulatory-agency-busi-
ness-plan-2020-to-2021 (accessed 3 July 2020).
8. Agrawal G, Parry B, Suresh B, Westra A. COVID-19
implications for life sciences R&D: Recovery and the




the-next-normal (accessed 3 July 2020).
9. ABPI. Life Sciences Recovery Roadmap, www.abpi.
org.uk/medicine-discovery/covid-19/life-sciences-
recovery-roadmap (accessed 10 September 2020).
10. UK Health Data Research Alliance, https://ukhealth-
data.org/about/ (accessed 10 August 2020).
11. Regulatory Horizons Council (RHC). GOV.UK, 2020,
https://www.gov.uk/government/groups/regulatory-
horizons-council-rhc (accessed 22 June 2020).
12. Ovseiko PV, Heitmueller A, Allen P, et al. Improving
accountability through alignment: the role of academic
health science centres and networks in England. BMC
Health Serv Res 2014; 14: 24.
13. Department for Business Energy and Industrial
Strategy and Life Sciences Organisation. Life Sciences
Sector Deal 2, www.gov.uk/government/publications/
life-sciences-sector-deal/life-sciences-sector-deal-2-2018
(2018, accessed 10 September 2020).
14. Clinical Trials Transformative Initiative, www.ctti-clin-
icaltrials.org/ (accessed 10 August 2020).
15. Hines PA, Janssens R, Gonzalez-Quevedo R, Lambert
A and Humphreys AJ. A future for regulatory science
in the European Union: the European Medicines
Agency’s strategy. Nat Rev Drug Discov 2020; 19:
293–294.
16. Innovative Medicines Initiative, European Medicines
Agency and U.S. Food and Drug Administration.
Collaborative research through public-private partner-
ship in support to advancing regulatory science, https://
www.imi.europa.eu/sites/default/files/uploads/docu-
ments/reference-documents/RegulatorySummit2019_
report.pdf (accessed 7 June 2020).
17. Department of Health and Social Care -Medicines and




18. MHRA Innovation Office – How we can help, www.
gov.uk/government/groups/mhra-innovation-office#
how-we-can-help (accessed 10 August 2020).
19. Coglianese C. Measuring Regulatory Performance.
Evaluating the impact of regulation and regulatory
policy. 59. Expert Paper No. 1, August 2012. https://
www.oecd.org/gov/regulatory-policy/1_coglianese%
20web.pdf (accessed 10 March 2020).
20. Association of the British Pharmaceutical Industry.
Bridging the skills gap in the biopharmaceutical industry:
maintaining the UK’s leading position in life sciences,
2019.
21. Oak Ridge Institute for Science and Education.
Research Participation Program at the U.S. Food
and Drug Administration (FDA), https://orise.orau.
gov/fda (accessed 10 March 2020).
22. STARS. Strengthening Training of Academia in
Regulatory Science (CSA STARS), www.csa-stars.eu/
index.html (accessed 10 March 2020).
23. The Organisation for Professionals in Regulatory
Affairs. The Organisation for Professionals in
Regulatory Affairs (TOPRA), https://www.topra.org/
(accessed 19 June 2020).
Calvert et al. 7
